• Molecular NameMoricizine
  • SynonymMoracizina [INN-Spanish]; Moracizine; Moracizinum [INN-Latin]
  • Weight427.525
  • Drugbank_IDDB00680
  • ACS_NO31883-05-3
  • Show 3D model
  • LogP (experiment)2.98
  • LogP (predicted, AB/LogP v2.0)3.44
  • pka6.4
  • LogD (pH=7, predicted)3.34
  • Solubility (experiment)0.000457 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.4
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors1
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds6
  • TPSA96.41
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA phenothiazine derivative with Vaughan Williams class Ic antiarrhythmic properties.
  • Absorption_value88.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability38.0
  • Protein binding95.0
  • Volume of distribution (VD)8.3 to 11.1 L/kg (oral administration); 185 to 210 L (intravenous (IV) administration).
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt undergoes extensive first-pass metabolism
  • Half life2~4 h (healthy individuals); 6 to 13 h (patients with arrhythmias).
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include vomiting, unconsciousness, and severe low blood pressure.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A